Ambys Medicines fetches $60 mln Series A
Redwood City, California-based Ambys Medicines, a developer of new medicines patients suffering from chronic liver diseases, has launched with $60 million in Series A financing. The investors were Third Rock Ventures and Takeda.
9 August 2018•1 min read
